European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Meta Expands AI Training With Employee Activity Tracking Tools 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SAN DIEGO, March 02, 2016 -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2015 financial results will be released on Wednesday, March 9, 2016 at 4:01 p.m. Eastern Time. Company management will host a conference call on Wednesday, March 9, 2016, at 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 58434612. The live audio webcast can be accessed via the Investor Relations’ section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus recently completed enrollment in its Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus has completed a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon, and plans to conduct additional clinical trials in patients with Raynaud’s phenomenon secondary to scleroderma. Apricus’ lead commercial product, Vitaros®*, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals) and Mylan NV. Apricus’ second-generation room temperature Vitaros is currently under development.
For further information on Apricus, visit http://www.apricusbio.com.
*Vitaros® is a registered trademark of NexMed International Limited. Such trademark is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck [email protected] The Trout Group LLC (646) 378-2933
